Immunic, Inc. (NASDAQ:IMUX - Get Free Report) Director Richard Alan Rudick acquired 87,300 shares of Immunic stock in a transaction that occurred on Tuesday, November 12th. The stock was acquired at an average price of $1.15 per share, with a total value of $100,395.00. Following the completion of the acquisition, the director now directly owns 87,300 shares in the company, valued at $100,395. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Immunic Trading Up 1.7 %
IMUX opened at $1.17 on Thursday. The firm's 50 day simple moving average is $1.45 and its two-hundred day simple moving average is $1.35. The company has a market capitalization of $105.39 million, a PE ratio of -0.95 and a beta of 1.88. Immunic, Inc. has a 1-year low of $0.97 and a 1-year high of $2.11.
Hedge Funds Weigh In On Immunic
A number of institutional investors have recently bought and sold shares of IMUX. BVF Inc. IL bought a new stake in Immunic during the 1st quarter worth approximately $11,752,000. Janus Henderson Group PLC purchased a new stake in shares of Immunic in the first quarter worth $9,266,000. Vanguard Group Inc. increased its stake in shares of Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company's stock worth $4,480,000 after purchasing an additional 1,703,047 shares in the last quarter. Ikarian Capital LLC lifted its stake in shares of Immunic by 258.3% during the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company's stock valued at $2,128,000 after buying an additional 1,162,378 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock valued at $169,000 after acquiring an additional 42,383 shares in the last quarter. 51.82% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold | Ad
Trump's back in the White House, but Wall Street is pissed.
Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.
A number of brokerages have recently issued reports on IMUX. EF Hutton Acquisition Co. I raised shares of Immunic to a "strong-buy" rating in a report on Monday, September 16th. Leerink Partners restated an "outperform" rating and issued a $5.00 target price on shares of Immunic in a report on Monday, September 9th. Leerink Partnrs upgraded shares of Immunic to a "strong-buy" rating in a research note on Monday, September 9th. StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a report on Monday. Finally, B. Riley initiated coverage on Immunic in a report on Tuesday, August 27th. They issued a "buy" rating and a $6.00 price objective for the company. One analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Immunic currently has a consensus rating of "Buy" and an average target price of $11.20.
Get Our Latest Stock Report on Immunic
Immunic Company Profile
(
Get Free Report)
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
